OKYO Pharma Ltd

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.42 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Mar 2025, as filed

Net income

$4.71M

Free cash flow

$1.81M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
15 Sep 2023	BRANCACCIO JOHN P Director	Bought	$25.01K	opened
19 May 2022	CERRONE GABRIELE M Executive Chairman	Bought	$440.80K	1.1%
19 May 2022	CERRONE GABRIELE M Non-Executive Chairman	Bought	$150.00K	150%
19 May 2022	JACOB GARY S Chief Executive Officer	Bought	$50.00K	opened
17 May 2022	CERRONE GABRIELE M Non-Executive Chairman	Bought	$96.69K	0.3%

22out of 100

Profitability 0

Financial strength 25

Growth n/a

Insiders 50

Strongest on insiders (50), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan